Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CMD-193 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CMD-193 | DRUG | - |
Inclusion Criteria: * Histologically confirmed malignant solid tumor that has progressed following standard therapy, or for which no standard effective treatment is available * Tumor expression of Lewis Y antigen ( \> or = 20% tumor cells positive for Lewis Y by immunohistochemistry assay) * Easter...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
CMD-193 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being evaluated in the oncology therapeutic area for patients with advanced malignant solid tumors.
CMD-193 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the safety and efficacy of this investigational oncology drug.
CMD-193 is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug is no longer in active clinical trials according to available data.
CMD-193 has been studied in one clinical trial, identified as NCT00161642, titled 'Study Evaluating CMD-193 in Advanced Malignant Solid Tumors.' This was a Phase 1, uncontrolled study conducted in the United States with 54 participants aged 18 years and older. The trial has been completed.
CMD-193 is the primary name used for this investigational drug in clinical trial records. No alternative names have been identified in the available information, so it is not known to be the same as any other marketed or investigational drug.